Adage Capital Partners
RGLS

Adage Capital Partners’s Regulus Therapeutics RGLS Stock Holding History

Adage Capital Partners’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,000,000
Closed -$3.16M – 925
2024
Q4 		$3.16M Hold
2,000,000
– – 0.01% 761
2024
Q3 		$3.14M Hold
2,000,000
– – 0.01% 751
2024
Q2 		$3.57M Sell
2,000,000
-1,679,854
-46% -$3.9M 0.01% 742
2024
Q1 		$10.6M Buy
+3,679,854
New +$6M 0.02% 588

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners's RGLS Position: Q1 2025 in Review

Adage Capital Partners sold out of Regulus Therapeutics (RGLS) in Q1 2025, closing a stake of 2,000,000 shares — an estimated $3.16M sold.

Adage Capital Partners first reported a position in RGLS in Q1 2024 and held it in 4 quarters. The position peaked at $10.6M in Q1 2024. 75 funds tracked by Wall St. Rank hold RGLS as of Q1 2025.

  • Adage Capital Partners reported no remaining Regulus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Adage Capital Partners sold 2,000,000 Regulus Therapeutics shares in Q1 2025, an estimated $3.16M.
  • Adage Capital Partners first reported a position in Regulus Therapeutics in Q1 2024 and held it in 4 quarters.
  • Adage Capital Partners's Regulus Therapeutics position peaked at $10.6M in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.